Retraction to: miR-34 increases in vitro PANC-1 cell sensitivity to gemcitabine via targeting Slug/PUMA

IOS Press has retracted the following publication from its online content:

[Cancer Biomarkers, 21(4) (2018), 755–762, DOI: 10.3233/CBM-170289]

miR-34 increases in vitro PANC-1 cell sensitivity to gemcitabine via targeting Slug/PUMA

Qing-An Zhanga, Xu-Hai Yangf, Dong Chenc, Xiang Yanb, Fu-Chun Jingd, Hong-Qian Liue and Ronghua Zhanga

a Department of Clinical Laboratory, The Central Hospital of Linyi, Yishui, Shandong, China

b Department of Oncology, Yantaiyuhuangding Hospital, Yantai, Shandong, China

c Department of General Surgery, The Affiliated Hospital of Qingdao University, Qingdao,Shandong, China

d Department of Gastroenterology, Taian Central Hospital, Taian, Shandong, China

e Department Pharmacy, The Central Hospital of Linyi, Yishui, Shandong, China

f Department of Hemopurification Center, Yantaiyuhuangding Hospital, Yantai, Shandong, China

The editorial office was contacted by researchers claiming that the article reported a wrongly identified nucleotide sequence reagent [1]. Assessment by the Editor-in-Chief found that the claim has significant impact on the article’s conclusions, which would need rectification. The corresponding author was not able to provide evidence to support a correction; therefore the article has been retracted.